Custom Anti-Idiotypic Antibody Production for Phosphorylation Research
Home / Services / Custom Antibody for Phosphorylation Research / Custom Anti-Idiotypic Antibody Production for Phosphorylation Research Custom Anti-Idiotypic Antibody Production for Phosphorylation Research
INQUIRYCreative BioMart is confident to provide our customers with unparalleled anti-idiotypic antibodies for their kinase/phosphatase biology research and pharmaceutical development projects. We offer a full range of customized services from antigen preparation to downstream analysis to ensure that our customers receive requested deliverables as soon as possible.
Background
An idiotype can be defined as a set of idiotopes present within the antibody complement determining regions (CDRs). Anti-idiotypic antibodies (anti-ID Abs) can bind to the idiotope of another antibody and are therefore antibody specific. These anti-idiotypic antibodies, capable of binding to therapeutic antibodies within biological fluids, are powerful tools for immunogenicity assays and PK/PD analysis during the development of therapeutic antibodies, allowing measurement of free or total drug levels in preclinical and clinical samples. In addition, they can also be used as positive controls in anti-drug antibodies (ADA) assays.
Protein phosphorylation, which plays a key role in many physiological processes, is often deregulated under pathological conditions. The current understanding of how kinases and phosphatases regulate phosphorylation events and thus coordinate cellular and organ functions makes them potential drug targets for the treatment of many diseases. Antibodies targeting kinases and phosphatases have been one of the most active and promising pipelines in the pharmaceutical industry. Anti-idiotype antibodies are expected to be used to better understand the efficacy of existing monoclonal therapeutics, to develop new therapeutic antibody candidates, and to evaluate biosimilars.
Figure 1. Schematic representation of the dual anti-idiotypic purification process to isolate a desired and properly paired BsAb (framed). (Godar M, et al., 2016)
Capabilities
Creative BioMart offers our extensive experience in the production of anti-idiotypic antibodies to maximize the chance to produce highly specific, sensitive and reproducible antibodies within a short period of time. We have successfully produced hundreds of custom anti-idiotypic antibodies for our customers worldwide.
Service Options
Creative BioMart offers extensive service options for anti-idiotypic antibodies. We will do our best to optimize the custom project based on antibody formats and their different application scenarios to perfectly meet your research requirements.
| Types of Anti-Idiotypic Antibodies | ||
Type 1
|
Type 2
|
Type 3
|
| Applications | ||
| Western blot | ELISA | Flow cytometry |
| Neutralization assay | Immunogenicity assay | ADA assay |
| Available Immunogens | ||
| Adalimumab | Atezolizumab | Bevacizumab |
| Brentuximab | Certolizumab pegol | Cetuximab |
| Daclizumab | Daratumumab | Denosumab |
| Durvalumab | Eculizumab | Etanercept |
| Gemtuzumab | Golimumab | Infliximab |
| Ipilimumab | Natalizumab | Nivolumab |
| Obinutuzumab | Omalizumab | Palivizumab |
| Panitumumab | Pembrolizumab | Ranibizumab |
| Rituximab | Satumomab | Solanezumab |
| Teplizumab | Tocilizumab | Trastuzumab |
| Ustekinumab | Vedolizumab | |
If you can't find what you are looking for in the options above, please fill out the online inquiry form and let us know more details.
Standard Service Process
Highlights
Creative BioMart provides comprehensive and flexible custom anti-idiotypic antibody production services to meet the individual needs of our customers. Our advanced technology platform coupled with a large product portfolio has enabled us to successfully complete numerous challenging projects, helping our customers save time and effort. If you are interested in our services or products, please do not hesitate to contact us.
References
- Godar M, et al. Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy. Scientific reports, 2016, 6(1): 1-12.
- Ameri M & Zhou E M. Idiotypes and anti-idiotypic antibodies: a review. Comparative Clinical Pathology, 2006,14(4): 171-178.